Table 12.6d

Immunosuppression Use: Antirejection Treatment from Transplant

to One Year Posttransplant, 1992 to 2001

Recipients with Lung Transplants

		Year of Transplant
		1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
Transplants		535	674	738	893	836	947	893	919	976	1,073
Tx with Antirejection Treatments		257	379	388	475	381	419	402	394	430	482
Antibodies	Category Usage	8.6%	14.2%	17.8%	9.5%	10.8%	11.7%	15.9%	16.2%	18.4%	11.8%
	ALG	0.0%	0.3%	1.3%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	ATG	0.8%	5.3%	10.3%	5.7%	7.1%	6.4%	10.2%	7.4%	7.0%	4.4%
	NRATG/NRATS	0.0%	0.0%	0.3%	0.0%	0.3%	1.4%	0.7%	0.8%	0.2%	0.0%
	OKT3	7.8%	9.5%	7.7%	4.2%	3.7%	4.3%	3.2%	3.0%	2.6%	1.5%
	Thymoglobulin	0.0%	0.0%	0.0%	0.2%	0.0%	0.0%	0.7%	5.1%	5.8%	6.2%
	Zenapax	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%	2.2%	1.0%	2.6%	0.8%
	Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%	0.8%	2.8%	0.6%
Corticosteroids	Category Usage	96.9%	91.0%	92.5%	93.7%	90.0%	94.0%	91.5%	92.9%	88.1%	92.1%
	Steroids	96.9%	91.0%	92.5%	93.7%	90.0%	94.0%	91.5%	92.9%	88.1%	92.1%

Source: OPTN/SRTR Data as of August 1, 2003.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.